Recommendations by the Spanish Society of Rheumatology on Osteoporosis.

[1]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[2]  A. Cohen.  Premenopausal Osteoporosis. , 2018, Endocrinology and metabolism clinics of North America.

[3]  P. Geusens,et al.  Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. , 2018, The lancet. Diabetes & endocrinology.

[4]  P. Geusens,et al.  Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  Jia-Guo Zhao,et al.  Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis , 2017, JAMA.

[6]  L. Carmona,et al.  Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis. , 2017, Seminars in arthritis and rheumatism.

[7]  R. Eastell,et al.  Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. , 2017, Bone.

[8]  P. Geusens,et al.  Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial , 2017, The Lancet.

[9]  Sonia M. Thomas,et al.  Comparisons of Interventions for Preventing Falls in Older Adults: A Systematic Review and Meta-analysis , 2017, JAMA.

[10]  W. Leslie,et al.  Trabecular bone score (TBS): Method and applications. , 2017, Bone.

[11]  A. Grauer,et al.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.

[12]  D. Bauer,et al.  Pain, Quality of Life, and Safety Outcomes of Kyphoplasty for Vertebral Compression Fractures: Report of a Task Force of the American Society for Bone and Mineral Research , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  Haifeng Guo,et al.  Bone fracture risk in patients with rheumatoid arthritis , 2017, Medicine.

[14]  Raveendhara R. Bannuru,et al.  2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis , 2017, Arthritis & rheumatology.

[15]  I. Lambrinoudaki,et al.  Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. , 2017, Maturitas.

[16]  Jacques P. Brown,et al.  10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. , 2017, The lancet. Diabetes & endocrinology.

[17]  Mary B Leonard,et al.  Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. , 2017, Kidney international.

[18]  A. Qaseem,et al.  Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. , 2017, Annals of internal medicine.

[19]  S. Polyzos,et al.  Clinical Features of 24 Patients With Rebound‐Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  J. Reginster,et al.  The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation , 2017, Oncotarget.

[21]  N. Watts,et al.  Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  N. Nigil Haroon,et al.  Bone Mineral Density and Fracture Risk in Ankylosing Spondylitis: A Meta-Analysis , 2017, Calcified Tissue International.

[23]  C. Cooper,et al.  Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG , 2017, Journal of bone oncology.

[24]  Zhiguo Xu.  Alendronate for the Treatment of Osteoporosis in Men: A Meta-Analysis of Randomized Controlled Trials , 2017, American journal of therapeutics.

[25]  W. Leslie,et al.  Trabecular Bone Score: A New DXA-Derived Measurement for Fracture Risk Assessment. , 2017, Endocrinology and metabolism clinics of North America.

[26]  V. Gudnason,et al.  Imminent risk of fracture after fracture , 2017, Osteoporosis International.

[27]  C. Roux,et al.  Imminent fracture risk , 2017, Osteoporosis International.

[28]  E. Lespessailles,et al.  Low-trauma fractures without osteoporosis , 2017, Osteoporosis International.

[29]  D. Dempster,et al.  Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  P. Miller,et al.  Observations following discontinuation of long-term denosumab therapy , 2017, Osteoporosis International.

[31]  R. Horne,et al.  International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates , 2017, Osteoporosis International.

[32]  Daniel B. Shin,et al.  The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study , 2017, Annals of the rheumatic diseases.

[33]  D. Kiel,et al.  Goal‐Directed Treatment for Osteoporosis: A Progress Report From the ASBMR‐NOF Working Group on Goal‐Directed Treatment for Osteoporosis , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  P. Geusens,et al.  EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures , 2016, Annals of the rheumatic diseases.

[35]  M. Chung,et al.  Calcium Intake and Cardiovascular Disease Risk , 2016, Annals of Internal Medicine.

[36]  Bin Chen,et al.  Increased risk of vertebral fracture in patients with rheumatoid arthritis , 2016, Medicine.

[37]  B. Vandermeer,et al.  Bisphosphonates for steroid-induced osteoporosis. , 2016, The Cochrane database of systematic reviews.

[38]  S. Fishman,et al.  Medial branch nerve block and ablation as a novel approach to pain related to vertebral compression fracture , 2016, Current opinion in anaesthesiology.

[39]  A. Grauer,et al.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis. , 2016, The New England journal of medicine.

[40]  C. Christiansen,et al.  Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. , 2016, JAMA.

[41]  G. Clark,et al.  Assessing the utility of serum C-telopeptide cross-link of type 1 collagen as a predictor of bisphosphonate-related osteonecrosis of the jaw: A systematic review and meta-analysis. , 2016, Journal of the American Dental Association.

[42]  Jacques P. Brown,et al.  Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates , 2016, The Journal of clinical endocrinology and metabolism.

[43]  K. Barker,et al.  Spinal Orthoses for Vertebral Osteoporosis and Osteoporotic Vertebral Fracture: A Systematic Review. , 2016, Archives of physical medicine and rehabilitation.

[44]  D. A. Pires-Oliveira,et al.  Effects of whole body vibration on bone mineral density in postmenopausal women: a systematic review and meta-analysis , 2016, Osteoporosis International.

[45]  J. Bagan,et al.  Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. , 2016, Oral diseases.

[46]  Jacques P. Brown,et al.  relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment , 2016 .

[47]  J. Kanis,et al.  Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal , 2016, Calcified Tissue International.

[48]  D. Bauer,et al.  Vertebral Fractures: Clinical Importance and Management. , 2016, The American journal of medicine.

[49]  K. Saag,et al.  Glucocorticoid-induced Osteoporosis , 2017, Indian journal of endocrinology and metabolism.

[50]  L. Brizeno,et al.  Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review , 2016, Medicina oral, patologia oral y cirugia bucal.

[51]  R. Liu,et al.  Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis , 2016, Osteoporosis International.

[52]  D. Bauer,et al.  Managing Osteoporosis in Patients on Long‐Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[53]  X. Nogués,et al.  Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014). , 2015, Revista clinica espanola.

[54]  M. Molokhia,et al.  Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis , 2015, BMJ Open.

[55]  X. Nogués,et al.  Clinical practice guidelines for postmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014) , 2015 .

[56]  C. Weaver,et al.  Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation , 2015, Osteoporosis International.

[57]  S. Polyzos,et al.  Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. , 2015, Metabolism: clinical and experimental.

[58]  W. Gulliver,et al.  Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative , 2015, The Journal of Rheumatology.

[59]  I. Reid,et al.  Calcium intake and risk of fracture: systematic review , 2015, BMJ : British Medical Journal.

[60]  Hang Lee,et al.  Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial , 2015, The Lancet.

[61]  A. Naranjo,et al.  Two-year adherence to treatment and associated factors in a fracture liaison service in Spain , 2015, Osteoporosis International.

[62]  D. Furst,et al.  FRI0059 Routine Assessment of Patient Index Data 3 (RAPID3) – Defined Remission is as Stringent as ACR/Eular Boolean-Defined Remission in a Clinical Trial of Patients with Early Rheumatoid Arthritis Treated with Abatacept , 2015 .

[63]  V. Strand,et al.  SAT0221 Efficacy and Safety of PF-04171327, a Novel Dissociated Agonist of the Glucocorticoid Receptor (DAGR): Results of a Phase 2, Randomized, Double-Blind Study , 2015 .

[64]  K. Saag,et al.  Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab , 2015, Arthritis & rheumatology.

[65]  E. Sasso,et al.  AB0246 Predictive Value of a Multi-Biomarker Disease Activity Score for Successful Dose Reduction of TNF Inhibitors in Rheumatoid Arthritis: Results of the Dress Study , 2015 .

[66]  G. Schett,et al.  SAT0056 Retro – Study of Reduction of Therapy in Patients with Rheumatoid Arthritis in Ongoing Remission , 2015 .

[67]  O. Phung,et al.  Increased risk for atypical fractures associated with bisphosphonate use. , 2015, Family practice.

[68]  P. Kannus,et al.  Exercise and vitamin D in fall prevention among older women: a randomized clinical trial. , 2015, JAMA internal medicine.

[69]  S. Cummings,et al.  The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON‐Pivotal Fracture Trial (PFT) , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[70]  R. Buchbinder,et al.  Percutaneous vertebroplasty for osteoporotic vertebral compression fracture. , 2015, The Cochrane database of systematic reviews.

[71]  James R. Rogers,et al.  Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis , 2015, PloS one.

[72]  J. Kanis,et al.  Adjusting Fracture Probability by Trabecular Bone Score , 2015, Calcified Tissue International.

[73]  G. Lyritis,et al.  Cost-effective osteoporosis treatment thresholds in Greece , 2015, Osteoporosis International.

[74]  F. Romero,et al.  Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis , 2015, Rheumatology International.

[75]  Amit S. Gupta,et al.  Are Men at High Risk for Osteoporosis Underscreened? A Quality Improvement Project. , 2015, The Permanente journal.

[76]  Manna Zhang,et al.  Association between alendronate and atypical femur fractures: a meta-analysis , 2015, Endocrine connections.

[77]  Sakae Tanaka,et al.  Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT) , 2015, Osteoporosis International.

[78]  L. Schipper,et al.  Treatment of osteoporosis in renal insufficiency , 2015, Clinical Rheumatology.

[79]  P. Duca,et al.  Improving adherence to and persistence with oral therapy of osteoporosis , 2015, Osteoporosis International.

[80]  J. Reginster,et al.  A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. , 2015, The Journal of clinical endocrinology and metabolism.

[81]  A. Sudo,et al.  Analysis of daily teriparatide treatment for osteoporosis in men , 2015, Osteoporosis International.

[82]  A. Díez-Pérez,et al.  [FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population]. , 2015, Medicina clinica.

[83]  Jacques P. Brown,et al.  Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[84]  J. Franco,et al.  [Atypical femoral fractures and bisphosphonates treatment: is it a risk factor?]. , 2014, Acta medica portuguesa.

[85]  P. Shekelle,et al.  Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures , 2014, Annals of Internal Medicine.

[86]  F. Cosman.  Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches , 2014, Current Osteoporosis Reports.

[87]  Jacques P. Brown,et al.  Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study , 2014, Osteoporosis International.

[88]  S. Cummings,et al.  Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? , 2014, The Journal of clinical endocrinology and metabolism.

[89]  Nicholas Harvey,et al.  The Osteoporosis Treatment Gap , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[90]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis International.

[91]  S. Cummings,et al.  Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. , 2014, JAMA internal medicine.

[92]  D. Hans,et al.  Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study , 2014, Osteoporosis International.

[93]  A. Avenell,et al.  Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. , 2014, The Cochrane database of systematic reviews.

[94]  N. Santesso.  Hip protectors for preventing hip fractures in older people , 2014, The Cochrane database of systematic reviews.

[95]  M. Stevenson,et al.  Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures: a systematic review and cost-effectiveness analysis. , 2014, Health technology assessment.

[96]  S. Silverman,et al.  The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group , 2014, Osteoporosis International.

[97]  Hang Lee,et al.  Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. , 2014, The Journal of clinical endocrinology and metabolism.

[98]  Victoria A Goodwin,et al.  Multiple component interventions for preventing falls and fall-related injuries among older people: systematic review and meta-analysis , 2014, BMC Geriatrics.

[99]  R. Francis,et al.  Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. , 2014, Health technology assessment.

[100]  N. Guañabens,et al.  Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis , 2013, Hepatology.

[101]  D. Matlock,et al.  "Due" for a scan: examining the utility of monitoring densitometry. , 2013, JAMA internal medicine.

[102]  C. Cooper,et al.  Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.

[103]  J. Shepherd,et al.  Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on Body Composition. , 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[104]  R. Rizzoli,et al.  SCOPE: a scorecard for osteoporosis in Europe , 2013, Archives of Osteoporosis.

[105]  C. Cooper,et al.  Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. , 2013, Maturitas.

[106]  D. Solomon,et al.  Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta‐analysis , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[107]  J. Nolla,et al.  [Assessment of a set of FRAX(®)-based criteria for the indication of bone densitometry in Spanish postmenopausal women]. , 2013, Medicina clinica.

[108]  V. Moyer.  Vitamin D and Calcium Supplementation to Prevent Fractures in Adults: U.S. Preventive Services Task Force Recommendation Statement , 2013, Annals of Internal Medicine.

[109]  Kim Brixen,et al.  Risk assessment tools to identify women with increased risk of osteoporotic fracture: Complexity or simplicity? A systematic review , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[110]  E. Chamizo Carmona,et al.  Systematic literature review of bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis. , 2013, Reumatologia clinica.

[111]  P. Geusens,et al.  Optimizing fracture prevention: the fracture liaison service, an observational study , 2013, Osteoporosis International.

[112]  M. Hiligsmann,et al.  Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group , 2013, Osteoporosis International.

[113]  R. Winzenrieth,et al.  Is bone microarchitecture status of the lumbar spine assessed by TBS related to femoral neck fracture? A Spanish case–control study , 2013, Osteoporosis International.

[114]  J. Eisman,et al.  Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis , 2013, Osteoporosis International.

[115]  S. Silverman,et al.  Incidence of atypical nontraumatic diaphyseal fractures of the femur , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[116]  L. Carmona,et al.  Calcium supplementation and kidney stone risk in osteoporosis: a systematic literature review. , 2012, Clinical and experimental rheumatology.

[117]  A. Díez-Pérez,et al.  FRAX® tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort , 2012, BMC Musculoskeletal Disorders.

[118]  S. Cummings,et al.  Treatment failure in osteoporosis , 2012, Osteoporosis International.

[119]  R. Eastell,et al.  Osteoporosis in men: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.

[120]  D. Felsenberg,et al.  Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension , 2012, Osteoporosis International.

[121]  C. Inderjeeth,et al.  Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments , 2012, Journal of Bone and Mineral Metabolism.

[122]  B. Abrahamsen,et al.  Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases , 2012, Osteoporosis International.

[123]  Myunghan Choi,et al.  Effectiveness of intervention programs in preventing falls: a systematic review of recent 10 years and meta-analysis. , 2012, Journal of the American Medical Directors Association.

[124]  R. Rizzoli,et al.  Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland , 2012, Osteoporosis International.

[125]  S. Cummings,et al.  The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT) , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[126]  B. Edwards,et al.  Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. , 2011, Journal of the American Dental Association.

[127]  Jacques P. Brown,et al.  Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? , 2011, Osteoporosis International.

[128]  Thomas D Brown,et al.  Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[129]  S. Cummings,et al.  Effects of denosumab on fracture and bone mineral density by level of kidney function , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[130]  C. Cooper,et al.  Interpretation and use of FRAX in clinical practice , 2011, Osteoporosis International.

[131]  R. Wallace,et al.  Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. , 2011, The American journal of clinical nutrition.

[132]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[133]  S. Beard,et al.  Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision , 2011, Osteoporosis International.

[134]  J. Kaufman,et al.  Towards a diagnostic and therapeutic consensus in male osteoporosis , 2011, Osteoporosis International.

[135]  S. Boonen,et al.  Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[136]  S. Perera,et al.  Height loss, vertebral fractures, and the misclassification of osteoporosis. , 2011, Bone.

[137]  C. Cooper,et al.  Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards , 2011, Osteoporosis International.

[138]  S. Cummings,et al.  Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. , 2011, Kidney international.

[139]  K. Zhu,et al.  Calcium supplementation and the risks of atherosclerotic vascular disease in older women: Results of a 5‐year RCT and a 4.5‐year follow‐up , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[140]  Rongwei Fu,et al.  Primary Care–Relevant Interventions to Prevent Falling in Older Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force , 2010, Annals of Internal Medicine.

[141]  David A Hanley,et al.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary , 2010, Canadian Medical Association Journal.

[142]  Jacques P. Brown,et al.  Efficacy and safety of a once‐yearly i.v. Infusion of zoledronic acid 5 mg versus a once‐weekly 70‐mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double‐blind, active‐controlled study , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[143]  S. Boonen,et al.  IOF position statement: vitamin D recommendations for older adults , 2010, Osteoporosis International.

[144]  Terrie E. Kitchner,et al.  The role of cigarette smoking and statins in the development of postmenopausal osteoporosis: a pilot study utilizing the Marshfield Clinic Personalized Medicine Cohort , 2010, Osteoporosis International.

[145]  A. Go,et al.  Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. , 2010, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[146]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[147]  L. Heaney,et al.  The safety of bisphosphonate use in pre-menopausal women on corticosteroids. , 2009, Current drug safety.

[148]  C. Gordon,et al.  European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies , 2009, Annals of the rheumatic diseases.

[149]  Rong-Sen Yang,et al.  Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta-analysis , 2009, Clinical rehabilitation.

[150]  Hang Lee,et al.  Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. , 2009, The Journal of clinical endocrinology and metabolism.

[151]  Jianting Chen,et al.  Anti-Fracture Efficacy of Risedronic Acid in Men , 2009, Clinical Drug Investigation.

[152]  S. Silverman,et al.  International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. , 2008, Bone.

[153]  Claus Christiansen,et al.  Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[154]  S. Boonen,et al.  Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[155]  S. Cummings,et al.  The effect of raloxifene treatment in postmenopausal women with CKD. , 2008, Journal of the American Society of Nephrology : JASN.

[156]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[157]  P. Tugwell,et al.  Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2024, The Cochrane database of systematic reviews.

[158]  S. Boonen,et al.  Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.

[159]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[160]  Richard Eastell,et al.  Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. , 2007, The Journal of clinical endocrinology and metabolism.

[161]  Jacques P. Brown,et al.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.

[162]  H. Genant,et al.  Enhanced prediction of fracture risk combining vertebral fracture status and BMD , 2007, Osteoporosis International.

[163]  S. Cummings,et al.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.

[164]  G. Oster,et al.  Compliance with drug therapy for postmenopausal osteoporosis , 2006, Osteoporosis International.

[165]  Krista F Huybrechts,et al.  Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. , 2006, Bone.

[166]  A. Wolk,et al.  Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women , 2006, Osteoporosis International.

[167]  S. Boonen,et al.  Safety and Efficacy of Risedronate in Patients With Age‐Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[168]  B. Canaud,et al.  [How to slow down parathyroid hormone (PTH) secretion without the risk of inducing an adynamic bone disease]. , 2005, Nephrologie & therapeutique.

[169]  S. Cummings,et al.  Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[170]  D. Black,et al.  Clinical Practice. Postmenopausal Osteoporosis. , 2005, The New England journal of medicine.

[171]  A. Silman,et al.  Predictive Value of BMD for Hip and Other Fractures , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[172]  Olof Johnell,et al.  Alcohol intake as a risk factor for fracture , 2005, Osteoporosis International.

[173]  Bess Dawson-Hughes,et al.  Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. , 2005, JAMA.

[174]  J. Cauley,et al.  Hip fracture in women without osteoporosis. , 2005, The Journal of clinical endocrinology and metabolism.

[175]  J. Kaufman,et al.  Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy , 2005, Osteoporosis International.

[176]  N. Watts,et al.  Official positions of the International Society for Clinical Densitometry. , 2004, Southern medical journal.

[177]  C. Christiansen,et al.  Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[178]  E. Barrett-Connor,et al.  Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[179]  C. Cooper,et al.  Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. , 2003, Arthritis and rheumatism.

[180]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[181]  M. Grabois,et al.  Health Professional's Guide to Rehabilitation of the Patient with Osteoporosis , 2003, Osteoporosis International.

[182]  A. Díez-Pérez,et al.  The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[183]  S. Cummings,et al.  Clinical use of bone densitometry: scientific review. , 2002, JAMA.

[184]  M. Hochberg,et al.  Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. , 2002, The Journal of clinical endocrinology and metabolism.

[185]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[186]  Susan R. Johnson,et al.  Osteoporosis prevention, diagnosis, and therapy. , 2001, JAMA.

[187]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[188]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[189]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[190]  P. Ebeling.  Osteoporosis in Men , 1999, Current opinion in rheumatology.

[191]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[192]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[193]  B. Wall,et al.  Revised radiation doses for typical X-ray examinations. Report on a recent review of doses to patients from medical X-ray examinations in the UK by NRPB. National Radiological Protection Board. , 1997, The British journal of radiology.

[194]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[195]  O. Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .

[196]  S. Cummings,et al.  Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.

[197]  C. Cooper,et al.  Rheumatoid arthritis, corticosteroid therapy and hip fracture. , 1995, Annals of the rheumatic diseases.

[198]  R. Holder,et al.  Generalised bone loss in patients with early rheumatoid arthritis , 1994, The Lancet.

[199]  C. Pak,et al.  Dose dependency of calcium absorption: A comparison of calcium carbonate and calcium citrate , 1988, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[200]  Judith E Adams,et al.  Opportunistic Identification of Vertebral Fractures. , 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[201]  S. Castañeda,et al.  [Therapeutic holidays in osteoporosis: Long-term strategy of treatment with bisphosphonates]. , 2016, Medicina clinica.

[202]  C. Cooper,et al.  Fracture experience among participants from the FROCAT study: what thresholding is appropriate using the FRAX tool? , 2016, Maturitas.

[203]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[204]  P. Vestergaard,et al.  Treatment of osteoporosis after alendronate or risedronate , 2015, Osteoporosis International.

[205]  H. Yoshikawa,et al.  The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis , 2015, Journal of Bone and Mineral Metabolism.

[206]  A. Sakuraba,et al.  Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[207]  C. Cooper,et al.  Changing trends in the epidemiology of hip fracture in Spain , 2013, Osteoporosis International.

[208]  J. Nolla,et al.  [Assessment of a set of FRAX(®)-based criteria for the indication of bone densitometry in Spanish postmenopausal women]. , 2013, Medicina clinica.

[209]  L. Carmona,et al.  Denosumab for the treatment of osteoporosis: a systematic literature review. , 2013, Reumatologia clinica.

[210]  J. Shepherd,et al.  Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. , 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[211]  A. Díez-Pérez,et al.  Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort. , 2012, Bone.

[212]  M. Alpéri,et al.  [Adverse effects of bisphosphonates]. , 2011, Reumatologia clinica.

[213]  P. Peris Bernal,et al.  Osteoporosis in young individuals , 2010 .

[214]  Sarah E Lamb,et al.  Interventions for preventing falls in older people living in the community. , 2009, The Cochrane database of systematic reviews.

[215]  B. Rovin,et al.  Teriparatide or alendronate in glucocorticoid-induced osteoporosis. , 2008, The New England journal of medicine.

[216]  P. Tugwell,et al.  Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2008, The Cochrane database of systematic reviews.

[217]  P. Tugwell,et al.  Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2008, The Cochrane database of systematic reviews.

[218]  S. Cummings,et al.  Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT) , 2003, Osteoporosis International.

[219]  O. Johnell,et al.  The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.

[220]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[221]  Claus Christiansen,et al.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. , 1994, World Health Organization technical report series.